Recent 8-K filings for ATAI

• July 16, 2026, 7:27 AM ET M&A materiality 1.00 positive item 1.01item 7.01item 9.01

  AtaiBeckley to be acquired by Eli Lilly for $6.75/share plus CVRs up to $2.50/share

  Merger consideration: $6.75 per share cash plus one CVR per share with potential milestone payments up to $2.50 per share.

• June 8, 2026, 5:00 PM ET other material materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×2

  AtaiBeckley shareholders elect three directors, ratify Deloitte as auditor at annual meeting

  Sabrina Martucci Johnson, Amir Kalali, and Andrea Heslin Smiley elected as Class I directors for three-year terms.

• June 3, 2026, 7:52 AM ET other material materiality 0.55 positive item 7.01

  AtaiBeckley to present at June 2026 conferences; will highlight BPL-003 Phase 3 initiation

  Jefferies Global Healthcare Conference fireside chat on June 3, 12:15 PM ET.

• May 12, 2026, 8:17 AM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  AtaiBeckley Q1 net loss $29.8M; BPL-003 Phase 3 initiation on track for Q2 2026

  Cash and equivalents $209.9M as of March 31, 2026; runway into 2029.

• March 9, 2026, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 9.01 ◈ Material Agreements ×2

  AtaiBeckley enters into new ATM equity offering agreement with Jefferies

  ATM allows AtaiBeckley to sell common stock via Jefferies as sales agent, replacing prior 2022 agreement.

• March 6, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  AtaiBeckley reports Q4/FY2025: net loss $660M; BPL-003 Phase 3 on track for Q2 2026

  Cash $220.7M as of Dec 31, 2025; runway to early 2029 topline readouts.

• March 6, 2026, 6:59 PM ET M&A materiality 0.65 negative item 8.01item 9.01

  AtaiBeckley reports pro forma combined net loss of $704M for 2025 after Beckley Psytech acquisition

  Pro forma combined net loss attributable to common stockholders $704.3M, or $3.11 per diluted share, for FY 2025.

• February 26, 2026, 6:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  AtaiBeckley reports positive Phase 2a results for EMP-01 in Social Anxiety Disorder; LSAS -11.85 vs placebo

  EMP-01 met primary safety objective; no serious AEs, no suicidal behavior.

• February 19, 2026, 6:59 PM ET leadership materiality 0.60 neutral item 5.02item 7.01item 9.01

  AtaiBeckley appoints Michael Faerm CFO effective March 9, 2026; Johnson becomes CAO

  Michael Faerm appointed CFO of AtaiBeckley, effective March 9, 2026; Anne Johnson becomes Chief Accounting Officer.

• January 8, 2026, 6:59 PM ET other material materiality 0.65 positive item 5.02item 7.01item 9.01

  AtaiBeckley provides 2026 milestones; BPL-003 Phase 3 start Q2'26, VLS-01 data H2'26

  BPL-003 (mebufotenin) Phase 2b TRD trial met primary and all key endpoints; Phase 3 guidance Q1'26, trial start Q2'26 pending FDA End-of-Phase 2 meeting.

• December 31, 2025, 6:59 PM ET other material materiality 0.55 positive item 1.01item 5.02item 3.03item 5.03item 5.01item 5.05item 7.01item 9.01 ◈ Governance Changes ×3

  AtaiBeckley completes redomiciliation to Delaware; stock continues trading as ATAI on Nasdaq

  Redomiciliation from Netherlands to Delaware completed on Dec 30, 2025; approved by ~99% of votes cast.

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.65 · Most common event other_material

7 positive 1 negative 3 neutral

source · ATAI on sec.gov